Pharmaceutical Non-Active Ingredients TRIZ Cases
- EphA5 Antibody-Drug Conjugates for Selective Carcinoma Therapy
EphA5-binding antibody-drug conjugates deliver cytotoxic payloads to cancer cells while reducing toxicity to healthy cells.
- EGFR Amphiphilic Ligand Conjugates for Immune Cell Activation
EGFR peptide–lipid conjugates target immune cells in lymph nodes to sustain activation and strengthen antitumor responses.
- Pre-Locked Hard-Shell Capsules with (Meth)Acrylate Coatings for Fast Filling
A pre-locked state supports machine separation, filling, and rejoining while the coating preserves capsule integrity.
- DUX4-Targeting siRNA Modifications for FSHD Gene Silencing
Chemical modifications in double-stranded siRNA target DUX4 mRNA for sequence-specific silencing in FSHD while limiting off-target effects.
- Ligand-Drug Conjugate Sugar Structures for Solubility and Clearance
Hydrophobic ligand-drug conjugates can aggregate and clear rapidly; hydrophilic sugar structures improve solubility and help control clearance.
- Film Coating Composition for Easier Mini-Tablet Swallowing
A graft copolymer and thickening agent form a slippery, cohesive coating that eases mini-tablet swallowing and supports taste masking.
- Cell-Reactive Compstatin Analogs for Sustained Complement Inhibition
Cell-reactive compstatin analogs remain associated with cell surfaces to sustain complement inhibition and protect against hemolysis.
- BRM/BRG1-Targeting Antibody-Drug Conjugates for Targeted Degradation
See how antibody-drug conjugates deliver E3 ligase-binding degraders to SMARCA2/4 while addressing limited efficacy and unwanted toxicity.
- Oligonucleotide-Based Proteolysis Targeting Chimeras for STAT3 Degradation
Because STAT3 lacks enzymatic activity, oligonucleotide PTCs recruit ubiquitin ligases to trigger targeted degradation through the proteasome.